Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)

Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)

IntroductionPegylated granulocyte colony-stimulating factor (G-CSF) has been widely used for preventing febrile neutropenia in various types of cancer treatment. In the present study, we prospectively evaluated the safety and efficacy of pegfilgrastim as a primary prophylaxis of febrile neutropenia...

Full description

Bibliographic Details
Main Authors: Ga-Young Song, Je-Jung Lee, Joon Ho Moon, Dajung Kim, Min Kyoung Kim, Hyo Jung Kim, Yeung-Chul Mun, Won-Sik Lee, Young Rok Do, Jae Hoon Lee, Sung-Hoon Jung, Jin Seok Kim
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Oncology
Subjects:
pegfilgrastim
prophylaxis
febrile neutropenia
multiple myeloma
pomalidomide
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1209110/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1209110/full

Similar Items